| Market Capitalization (Millions $) |
253,061 |
| Shares
Outstanding (Millions) |
1,377 |
| Employees |
3,000 |
| Revenues (TTM) (Millions $) |
3,314 |
| Net Income (TTM) (Millions $) |
-860 |
| Cash Flow (TTM) (Millions $) |
-367 |
| Capital Exp. (TTM) (Millions $) |
572 |
Beigene Ltd
BeiGene Ltd is a globally recognized, commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative and targeted oncology therapeutics for patients across the globe. It was founded in 2010 in China by Dr. John Oyler and continues to operate with a primary focus on developing and commercializing innovative immuno-oncology medicines for patients with cancer.
Over the years, the company has expanded and become an integrated global biopharmaceutical company. It currently boasts of a comprehensive portfolio of oncology assets that includes both commercial-stage products and clinical candidates. The company aims to provide cancer therapies that are supported by extensive clinical research and innovative medicines that are tailored to meet the unique genetic and molecular characteristics of tumors.
Beigene Ltd's most successful product to date is the anti-PD-1 antibody Tislelizumab, which is approved by China's National Medical Products Administration (NMPA) for the treatment of various types of cancer. It is also in advanced clinical development for multiple cancer indications in the US and other regions across the world.
In addition to Tislelizumab, the company has an extensive pipeline on multiple late-stage clinical programs, including the Bruton tyrosine kinase (BTK) inhibitor, Zanubrutinib, an investigational RXDX-106, a small molecule selective inhibitor of mutant RET for the treatment of solid tumors, and several other candidate therapies in advanced stages of clinical development.
The company's innovative and globally recognized research and development program have positioned it to become a leader in developing clinically differentiated and unique oncology drugs. Its therapeutic approach employs targeted and precision medicine-based solutions to combat and eradicate cancer cells.
As a result of its remarkable efforts, BeiGene Ltd has entered into numerous strategic collaborations with major global pharmaceutical companies to develop innovative therapies for patients with cancer. These collaborations have not only expanded the company's global reach but also broadened its expertise and capabilities in the development of innovative oncology drugs.
Beigene Ltd is committed to applying its vast scientific expertise and resources towards making significant progress in oncology treatment for patients globally. The company boasts a truly global presence with headquarters in Beijing, China and its research center in Massachusetts, USA; and offices in Europe and other regions across the globe. With its core focus on developing and offering innovative cancer therapies that cater to the specific health needs of patients across the globe, BeiGene Ltd continues to remain a leader in the global biopharmaceutical industry.
Company Address: c/o Mourant Governance Services (Cayman) Limited Grand Cayman 0
Company Phone Number: 949-4123 Stock Exchange / Ticker: NASDAQ BGNE
|
1.74% 
50.49 %